ArticleKidney international2013
How to find a prognostic biomarker for progressive diabetic nephropathy.
Article in Kidney international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Metabolomics approaches for the early detection and therapeutics: type 2 diabetes-induced diabetic kidney disease-a systematic review and meta-analysis.Metabolomics : Official journal of the Metabolomic Society · 2025Pooled it
- Dickkopf-3 (DKK3) in Urine Identifies Patients with Short-Term Risk of eGFR Loss.Journal of the American Society of Nephrology : JASN · 2018Trial
- Evaluation of urinary haptoglobin level as a biomarker of diabetic nephropathy in children with type 1 diabetes.Pediatric nephrology (Berlin, Germany) · 2023Article
- Detection and Characterization of a Biochemical Signature Associated with Diabetic Nephropathy Using Near-infrared Spectroscopy on Tissue Sections.Journal of clinical medicine · 2019Article
- Urinary Proteomics for the Early Diagnosis of Diabetic Nephropathy in Taiwanese Patients.Journal of clinical medicine · 2018Article
- Increased urinary angiotensin converting enzyme 2 and neprilysin in patients with type 2 diabetes.American journal of physiology. Renal physiology · 2018Article
- Urine biomarkers of tubular injury do not improve on the clinical model predicting chronic kidney disease progression.Kidney international · 2017Article
- Nonblood/urine biomarker of progression of kidney disease in diabetes mellitus.Clinical journal of the American Society of Nephrology : CJASN · 2015Article
- Article
- The diabetic rat kidney mediates inosituria and selective urinary partitioning of D-chiro-inositol.Experimental biology and medicine (Maywood, N.J.) · 2015Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
As a prognostic biomarker for progression of diabetic nephropathy, albuminuria fails in terms of sensitivity and specificity. Better urinary or plasma biomarkers are needed that can predict which diabetic patients are at highest risk for progression. Bhensdadia et al. report proteomic investigations that identified urinary haptoglobin as a potential prognostic biomarker for progressive diabetic nephropathy. Although as a single marker urinary haptoglobin adds little to albuminuria, together the two appear to provide better diagnostic accuracy than albuminuria alone.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.